STERIS Announces Financial Results for Fiscal 2027 First Quarter

STERIS delivers solid growth but faces cash flow pressure and long-term restructuring costs.

Risk flags

• ●Cash flow is under pressure, with net cash from operations declining to $367.1 million from $420.0 million and free cash flow dropping to $279.6 million from $326.5 million. This trend raises questions about the company's ability to fund increased capital expenditures and restructuring costs without further impacting liquidity.
• ●The restructuring plan involves $55–$70 million in pre-tax charges and $450 million in capital expenditures, but benefits are projected over a multi-year period ending in fiscal 2030. Execution risk is high, as delays, cost overruns, or failure to achieve operational efficiencies could erode projected returns.
• ●Forward-looking claims about innovation, capacity expansion, and network optimization are aspirational, with no supporting metrics or concrete milestones disclosed. The lack of quantified targets or interim progress updates makes it difficult to assess whether these goals are achievable or on track.
• ●Segment subcategory growth rates (e.g., service, consumables, capital equipment) are presented only as percentages, without corresponding dollar values or prior-year comparisons. This limits transparency and prevents independent verification of the most granular performance claims.
• ●The company reiterates prior guidance for revenue and earnings but does not disclose the original figures, making it impossible to assess whether guidance has changed or is being met. This omission reduces the clarity of forward-looking expectations.

Bottom line

STERIS’s first quarter results show broad-based revenue and profit growth, but declining cash flow and a capital-intensive restructuring plan introduce new financial and execution risks. The company’s narrative is credible at the headline level, with realised gains in revenue and income, but the long-term nature of the restructuring means operational benefits are years away. Claims about innovation and efficiency are not backed by measurable targets or timelines, and the lack of detailed segment data reduces transparency. Investors should focus on whether cash flow stabilizes as capital spending ramps up, and watch for concrete evidence that the restructuring is delivering promised efficiencies. The most important takeaway is that while current operations are strong, the path to value from restructuring is long and carries significant uncertainty.

Announcement summary

(NYSE: STE) STERIS plc announced financial results for its fiscal 2027 first quarter ended June 30, 2026, reporting total revenue of $1.5 billion, a 7% increase compared with $1.4 billion in the first quarter of fiscal 2026. Net income for the first quarter was $200.1 million, or $2.04 per diluted share, up from $177.4 million, or $1.79 per diluted share, in the prior year period. Adjusted net income was $253.4 million, or $2.59 per diluted share, compared with $231.2 million, or $2.34 per diluted share, in the previous year’s first quarter. Healthcare segment revenue grew 8% to $1.05 billion, with service revenue up 10%, consumable revenue up 9%, and capital equipment revenue up 1%. STERIS announced a targeted restructuring plan associated with a new Formulated Chemistries Center of Excellence in North Carolina, with anticipated pre-tax restructuring charges of approximately $55 million to $70 million, including $40 million to $50 million of cash expenditures and $15 million to $20 million of non-cash charges. The company projects as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7% for fiscal 2027, with adjusted earnings per diluted share anticipated to be in the range of $11.10 to $11.30. Capital expenditures are now anticipated to be approximately $450 million, and free cash flow is expected to be approximately $800 million.

Disagree with this article?